TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04128540

Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..
Study: NCT03847610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxymethyl Penicillin
Description: Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
Study: NCT01235962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Study: NCT00087646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po daily for 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po daily for 72 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po daily for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000/1200mg po daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 72 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks
Study: NCT05401305

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine for the prevention of infections caused by Haemophilus influenza type b
Description: The vaccine is administered into the region of the deltoid muscle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is administered into the region of the deltoid muscle
Study: NCT03504592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Completion of Glucose logs
Description: Glucose logs will be assessed by provider for completeness and accuracy
Study: NCT04204551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
Study: NCT00505076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0777
Description: MK-0777 GEM, 8 mg BID
Study: NCT03504592

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Completion of Glucose logs
Description: Glucose logs will be assessed by provider for completeness and accuracy
Study: NCT03462056

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cystic Fibrosis Ready to Use Supplemental Food
Description: Specially formulated for use by children with Cystic Fibrosis
Study: NCT00505076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0777
Description: MK-0777 GEM, 3 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets placebo BID
Study: NCT02697149

Intervention type: RADIATION
Intervention: nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
Description: All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.

Intervention type: RADIATION
Intervention: standard endoscopic retrograde cholangiopancreatography
Description: Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
Study: NCT02291016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
Study: NCT03298971

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).

Intervention type: OTHER
Intervention: Questionnaires
Description: Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
Study: NCT04093024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT01499706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-session of telephone-administered motivational interviewing
Description: Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-session telephone-administered motivational interviewing
Description: Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
Study: NCT03287518

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WAK2017
Description: WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
Study: NCT03138980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BodiMojo Buddy for IBS
Description: Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature.
Study: NCT01485692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol+promethazine
Description: haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol + midazolam
Description: haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
Study: NCT00687284

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT01409603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral
Study: NCT00271284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine / insulin glargine
Description: insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glulisin / insulin detemir
Description: insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
Study: NCT02215941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 8% ointment
Study: NCT01409603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral
Study: NCT02215941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 8% ointment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-45070
Description: TV-45070 8% ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00262054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
Study: NCT01409603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral
Study: NCT00744900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed, cisplatin
Description: Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
Study: NCT03050580

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-esteem enhancement group
Description: Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care for abused women
Description: The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
Study: NCT01228123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RRT for acute kidney failure using the CVVH method
Description: patients randomized to receive CVVH

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RRT for acute kidney failure using the IHD (intermittent HD)
Description: patients randomized to receive IHD
Study: NCT04009993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-BIRTHPERFORM digital tool
Description: use of A-BIRTHPERFORM digital tool
Study: NCT04269109

Intervention type: OTHER
Intervention: Multi-modal Opioid Sparing Pain Management Protocol
Description: Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.

Intervention type: OTHER
Intervention: Multi-modal Opioid Sparing Pain Management Protocol
Description: Incorporating multimodal opioid sparing ERAS techniques for cardiac surgery patients should show a decrease in the amount of opioids received, reduction in incidence of chronic pain, ileus, delirium, and potential for opioid addiction post-operatively. Between the dates of November 2018 through February 2019, a multi-modal, opioid sparing pain management protocol was evolving and a protocol was put into place. This study will compare outcomes before and after implementation of the protocol between the dates of September 1, 2018 - October 31, 2018 and March 1, 2019 - April 30, 2019.
Study: NCT02281019

Intervention type: PROCEDURE
Intervention: ERCP (Endoscopic Retrograde Cholangiopancreatography)
Description: ERCP procedure will be performed to visualize bile ducts.

Intervention type: PROCEDURE
Intervention: ERCP (Endoscopic Retrograde Cholangiopancreatography)
Description: ERCP procedure will be performed to visualize bile ducts.

Intervention type: PROCEDURE
Intervention: ERCP (Endoscopic Retrograde Cholangiopancreatography)
Description: ERCP procedure will be performed to visualize bile ducts.

Intervention type: DEVICE
Intervention: SpyGlass DVS and SpyGlass Digital Simple (DS)
Description: Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed

Intervention type: DEVICE
Intervention: SpyGlass DVS and SpyGlass Digital Simple (DS)
Description: Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed

Intervention type: DEVICE
Intervention: SpyGlass DVS and SpyGlass Digital Simple (DS)
Description: Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
Study: NCT01656863

Intervention type: OTHER
Intervention: Questionnaire
Study: NCT03056118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-month dual anti-platelet therapy
Description: Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 12-month dual anti-platelet therapy
Description: Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zotarolimus eluting stent
Description: Zotarolimus eluting stent is applied to coronary stenotic lesion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus eluting stent
Description: Biolimus eluting stent is applied to coronary stenotic lesion
Study: NCT03104725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Oral

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Each participant undergoes a baseline lumbar puncture (LP 1) as an inpatient at the NIH Clinical Center to obtain cerebrospinal fluid (CSF) for assays of Cys-DA, 3,4-dihydroxyphenylacetic acid (DOPAC), and related biochemicals. The second LP (LP 2) is completed after the PD participant has taken at least 5 doses of NAC (2 grams orally twice per day) and approximately 2 hours after the last NAC dose. For the HV participant, LP 2 occurs approximately 48 hours after LP 1 (no NAC administered).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: If needed for lumbar puncture

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: If needed for lumbar puncture
Study: NCT01358903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Cohorts receiving multiple escalating doses iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5429083
Description: Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression